NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Takeover premiums, stronger earnings and resilient drug demand give Wall Street fresh reasons to look beyond the market’s familiar favorites.
Wall Street’s most encouraging stories do not always arrive wearing the same uniform. On October 29, they came dressed as a home-security…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Nvidia-backed biotech pairs a clinical-stage cancer pipeline with pharmaceutical partnerships as TRex Bio, Retension and Lycia join the IPO queue
October 8, 2026
Artificial intelligence has spent the past several years promising to transform drug discovery. Iambic Therapeutics is now asking Wall…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Two new funds, institutional backing and a pharmaceutical heavyweight give the European life sciences investor fresh capital to turn promising science into investable businesses.
Biotechnology has never suffered from a shortage of ambitious ideas. Financing them is another matter. Forbion has just…
Oura’s proposed Nasdaq debut under OURA is shaping up as more than another wearable-device listing. It is a high-growth health-intelligence story built around a deceptively simple object: a screenless ring that turns sleep, stress, activity, heart health, metabolic health, and women’s health data into…
Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…
The market’s most investable theme today is not simply artificial intelligence, healthcare or macroeconomics in isolation. It is possibly the increasingly visible convergence of all three: businesses finding ways to monetize AI, healthcare platforms turning operational discipline into financial leverage, and policymakers…
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has delivered the kind of Phase 3 result biotechnology investors wait patiently—and, on occasion, not so patiently—for. The company reported that avexitide reduced the composite rate of severe and clinically meaningful post-bariatric hypoglycemia events by 55% versus…